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To the Editor: Since the initial reports describing the usefulness of
computed tomography angiography (CTA) with 4-row multislice
compute tomography (MSCT) for the examination of the coro-
nary arteries, the number of detector rows has been further
increased. Now, 256-row area detector CT (256-row CT) has been
developed, and a prototype system has been installed at our
institution. The diagnostic accuracy of coronary CTA with 256-
row CT for the evaluation of stenoses was compared with that of
conventional invasive coronary angiography (CAG) in this study.
The subjects were 10 patients (6 men and 4 women, mean age
69  10 years) with suspected coronary artery disease who were
examined by invasive CAG and who underwent coronary CTA
with 256-row CT within 2 weeks before or after CAG during the
period from January to April 2006. All patients showed sinus
rhythm. The coronary arteries were divided into 15 segments
according to the American Heart Association classification. Eval-
uation focused on coronary arteries 1.5 mm or more in lumen
diameter. Regions containing stents and stenotic lesions for which
percutaneous coronary intervention (PCI) had been performed
within the preceding 2 weeks were excluded from the evaluation.
The presence of stenoses of 50% or more was investigated with
coronary CTA and invasive CAG, and the results were compared.
Before the start of this clinical study, approval was obtained from
our institution’s ethics review board and informed consent to
participate in the study was obtained from each patient.
The system used was a prototype 256-row CT scanner with an
overall detector width of 128 mm (256  0.5 mm) (1,2), meaning
that a range of 128 mm can be covered in a single rotation of the
X-ray tube, and it is therefore not necessary to employ helical
scanning. The scanning protocol for coronary CTA was a 3-s
dynamic scan without electrocardiography (ECG) gating, a tube
voltage of 135 kV, a tube current of 330 mA, and a scan speed of
0.5 s/rotation. First, 50 ml of contrast medium was injected
intravenously at 4.0 ml/s, then a mixture of 10 ml of contrast
medium and 10 ml of saline solution was injected at 4.0 ml/s, and
finally a 20-ml saline flush was injected at 4.0 ml/s. Images were
reconstructed by the retrospective ECG-gated half-scan recon-
struction method with a single cardiac cycle or by the segmented
reconstruction method with multiple cardiac cycles. Each coronary
artery segment was visually evaluated in curved multiplanar refor-
mation and cross-sectional images by 2 investigators who were
blinded to the results of invasive CAG. Conventional invasive
CAG images were acquired with standard methods. The images
were evaluated by 2 investigators who were blinded to the results
of 256-row CT imaging.
Representative cases are shown in Figure 1. In the 10 patients,
108 coronary artery segments were investigated. The heart rate
during scanning ranged from 51 to 76 beats/min (mean  SD,
60.5  7.9 beats/min), with the heart rate variation ranging from
0 to 7 beats/min. Ten regions were found to be difficult to evaluate,
owing to extensive calcification. No regions were found to be
difficult to evaluate because of discontinuities caused by motion
artifacts or banding artifacts. In invasive CAG studies, 15 stenoses
were identified in 7 patients. Compared with CAG for the
detection of significant stenotic lesions, the sensitivity, specificity,
and positive and negative predictive values of 256-row CT were
100% (15 of 15), 89% (83 of 93), 60% (15 of 25), and 100% (83 of
83), respectively, when severe calcification was assumed to be
stenosis. When severe calcification was excluded, the sensitivity,
specificity, and positive and negative predictive values were 100%
(11 of 11), 95% (83 of 87), 73% (11 of 15), and 100% (83 of 83),
respectively.
These results are comparable to those that have been obtained
for 64-row CT, which has been reported to have a sensitivity of
73% to 94% and a specificity of 95% to 97% (3). The technical
limitations of the prototype 256-row CT system are: 1) a slower
rotation speed (0.5 s/rotation); 2) the inability to perform prospec-
tive ECG-gated scanning; and 3) the lack of an ECG dose
modulation function, as has already been implemented in current
64-row CT systems. Therefore the temporal resolution is lower
than that of a 64-row CT system. Nevertheless, no blood vessels
were found to be difficult to evaluate because of discontinuities
caused by motion artifacts or banding artifacts, and the diagnostic
accuracy was comparable to that of 64-row CT. One of the reasons
was that the data acquisition time was shorter and, as a result,
variations in heart rate were minimized. In case 1, motion artifacts
due to inadequate breath-holding were observed in the images
reconstructed by segmented reconstruction with 3 cardiac cycles.
However, images reconstructed by half-scan reconstruction did not
show motion artifacts. Therefore, 256-row CT has the potential to
respond flexibly to arrhythmias and variations in heart rate and is
also suitable for examining patients who cannot hold their breath.
Another reason for the favorable results was that isophasic images
(i.e., images with no temporal differences in the longitudinal
direction) were obtained, because helical scanning was not em-
ployed, and therefore the coronary arteries were depicted with
good continuity visually in the longitudinal direction. Recently,
dual-source CT systems have been introduced. Such CT systems
are equipped with 2 sets of X-ray tubes and detectors, allowing
images to be acquired at a temporal resolution of 83 ms with the
half-scan reconstruction method (4,5). Because multiple cardiac
Journal of the American College of Cardiology Vol. 51, No. 7, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
Published by Elsevier Inc.
cycles are needed to depict the coronary arteries when helical
scanning is employed, it is likely that 256-row CT will have
advantages in terms of the continuity of coronary artery images.
However, dual-source CT is considered to have the advantages of
higher temporal resolution and increased stability. It is therefore
anticipated that a system that incorporates the advantages of both
systems will be developed as further advances are made in CT
technologies. In this study, we performed 3-s dynamic scanning
without ECG dose modulation. The effective dose/scan calculated
from the simulation results was 33.3 mSv, which is higher than the
average effective dose of 14.2 mSv for a 64-row CT system at our
institution. With 256-row CT, imaging in the Z-axis direction in
the same time phase is possible in a single scan without the need
to employ helical scanning. Therefore, if prospective ECG gated
scanning could be performed in combination, a reduction in the
exposure dose to 3 to 4 mSv should be possible.
It is expected that an ECG-gated scan function and exposure
dose reduction functions will be available in commercial products.
The scan speed should be improved to the same level as that of a
64-row CT system by the time the system reaches the market.
Because the number of subjects in this study was small (10
patients), owing to the short evaluation period, when the 256-row
CT system becomes commercially available with these functions
provided, it will be necessary to evaluate its diagnostic capabilities
in a larger number of patients.
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Figure 1 Case 1
The heart rate during scanning was 65 to 66 beats/min. The images were reconstructed by half-scan reconstruction with 1 cardiac cycle. (A) A stenosis is demonstrated
in right coronary artery (RCA) #2 by invasive coronary angiography. (B) A computed tomography curved multiplanar reformation image shows a stenosis at the corre-
sponding location. (C) The stenosis can also be identified in the volume-rendered image. (D) A cross-sectional image shows a stenosis at the corresponding location. Ao
 aorta; LAD  left anterior descending coronary artery.
774 Correspondence JACC Vol. 51, No. 7, 2008
February 19, 2008:773–7
REFERENCES
1. Mori S, Endo M, Obata T, et al. Clinical potentials of the prototype
256-detector row CT-scanner. Acad Radiol 2005;12:148 –54.
2. Kondo C, Mori S, Endo M, et al. Real-time volumetric imaging of
human heart without electrocardiographic gating by 256-detector row
computed tomography: initial experience. J Comput Assist Tomogr
2005;29:694 – 8.
3. Cordeiro MAS, Lima JAC. Atherosclerotic plaque characterization by
multidetector row computed tomography angiography. J Am Coll
Cardiol 2006;47:C40 –7.
4. Achenbach S, Ropers D, Kuettner A, et al. Contrast-enhanced coronary
artery visualization by dual-source computed tomography—initial ex-
perience. Eur J Radiol 2006;57:331–5.
5. Johnson TR, Nikolaou K, Wintersperger BJ, et al. Dual-source CT
cardiac imaging: initial experience. Eur Radiol 2006;16:1409 –15.
Letters to the Editor
Switching Thienopyridines:
Hypothetical Versus Real Risks
I enjoyed reading the quality paper by Campo et al. (1) that tried
to determine whether platelet response after thienopyridines is
drug or class specific in a broad spectrum of post-stent patients.
The team should be acknowledged for the effort and for realistic
rates for low response after clopidogrel (21%), and ticlopidine
(19%). The major take-home message conveyed to the readership
is that clopidogrel-treated patients may be switched to ticlopidine
if “resistance” is determined by the platelet tests. However, the
practical implications of this idea are not obvious, may be danger-
ous, may not be supported by clinical or epidemiologic evidence,
and deserve at least some clarification and/or adjustment.
In fact, low response to clopidogrel as a major risk factor for the
worsened vascular outcomes has been suspected but never proven
to be a real clinical phenomena, especially considering that no load
75 mg clopidogrel saved 119 lives, and provided an absolute
mortality benefit after myocardial infarction in COMMIT
(Clopidogrel and Metoprolol in Myocardial Infarction Trial)
( 2 ). Also, none of the small observation studies monitor
compliance by measuring clopidogrel metabolites in plasma.
Therefore, “clopidogrel resistance” is a laboratory finding,
rather than a clinically relevant hazard unless further random-
ized evidence became available (3 ).
On the other hand, substituting clopidogrel with ticlopidine
definitely increases the bone marrow toxicity risks. Indeed, neu-
tropenia and thrombocytopenia were 2-fold higher in the ticlopi-
dine arm than in patients treated with clopidogrel in CLASSICS
(Clopidogrel Aspirin Stent International Cooperative Study) (4).
Doubled cytotoxicity rates after ticlopidine were confirmed in a
post-stent study (5) and a recent meta-analysis of 11,668 patients
(6). Therefore, the suggestion that in case of low platelet response
after clopidogrel patients should be switched to ticlopidine is not valid.
Unless there is proof that response after clopidogrel is indeed linked to
the clinical outcomes, monitoring compliance and potential tailoring
of dual antiplatelet regimens with aspirin and clopidogrel will be a
safer alternative than switching thienopyridines.
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Reply
We welcome the thoughtful comments by Dr. Serebruany to our
recent publication on clopidogrel poor responsiveness in a broad
population undergoing coronary stenting (1). Our major focus was
to assess whether clopidogrel poor responders display inadequate
platelet inhibition also after ticlopidine administration. We found
that the great majority (83%) of patients who were clopidogrel
nonresponders became responsive to ticlopidine, reaching a higher
level of platelet inhibition (platelet aggregation [PA] 69  15 vs.
44  18; p  0.01).
On the other hand, 23 patients who were responsive to
clopidogrel showed resistance to ticlopidine and correspondingly
less platelet inhibition with this drug (PA 46  15 vs. 70  15;
p  0.01).
When taken together our findings strongly suggest that poor
responsiveness to currently commercially available thienopyridines
may frequently be a drug-specific more than a class-effect mech-
anism. This conclusion holds particularly true in consideration that
in the currently recommended regimen ticlopidine at steady state
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